Dexcom Patient Assistance Program for US Patients During the COVID-19 Pandemic

The Dexcom Patient Assistance Program (“Program”) will be available to current U.S. customers who have lost their health insurance coverage as a result of the impact of the COVID-19 pandemic.* The Program will launch in the next several weeks and will be available during the COVID-19 pandemic in the United States.

For those existing U.S. customers who qualify for participation in Dexcom’s Program, Dexcom will offer:

• Up to two shipments of 90-days of Dexcom continuous glucose monitoring (“CGM”) system supplies, with each shipment consisting of one transmitter and three boxes of three sensors
• Reduce patient cost to $45 per 90-day supply shipment

*Patients that are eligible for coverage of their Dexcom CGM systems under a federal or state government program (such as Medicare, Medicaid or VA benefits) are not eligible to participate in this Program. Certain terms and conditions will apply to be eligible for participation in the Program, such as the submission of a complete Program application and documentation showing loss of healthcare benefits.